Growth of Medicare Advantage After Plan Payment Reductions.


Journal

JAMA health forum
ISSN: 2689-0186
Titre abrégé: JAMA Health Forum
Pays: United States
ID NLM: 101769500

Informations de publication

Date de publication:
02 Jun 2023
Historique:
medline: 26 6 2023
pubmed: 24 6 2023
entrez: 24 6 2023
Statut: epublish

Résumé

Various policy proposals would reduce federal payments to Medicare Advantage (MA) plans. However, it is unclear whether payment reductions would compromise beneficiary access to the MA program. To quantify the association between MA payment reductions under the Affordable Care Act (ACA) and MA enrollment growth. This retrospective cohort study examined the MA market before and after the ACA, which mandated cuts to MA benchmark payment rates. Using 2008 to 2019 county-level enrollment and payment data, a difference-in-differences analysis was conducted comparing MA enrollment changes between counties with larger vs smaller benchmark reductions, before vs after the ACA. The primary outcome was the MA enrollment rate, defined as the proportion of a county's Medicare beneficiaries enrolled in MA. A secondary analysis examined MA plan payments per member per month. Among 3138 counties with 37 639 county-year observations, ACA-induced benchmark cuts were sizeable and varied, ranging from 0% to 42.9% (mean [SD], 5.9% [6.6%]). Counties with benchmark cuts above the 75th percentile had population-weighted average benchmark cuts of 14.9% compared with 4.4% in other counties. In the 8 years following the ACA, there was no differential change in MA enrollment between counties with larger vs smaller benchmark cuts (difference-in-differences estimate, 0.02 [95% CI, -1.18 to 1.21] percentage points; P = .98). Plan payments differentially fell in counties with larger benchmark cuts by $78.35 (95% CI, $62.21-$94.48) per member per month (P < .001). This cohort study found no evidence that the MA benchmark and ensuing payment cuts imposed by the ACA were associated with reduced MA enrollment, compromising access to MA. This evidence can inform ongoing policy debates regarding the growth of MA, concerns about excess payments to MA plans, and proposed Medicare reforms, including further reductions in MA payments.

Identifiants

pubmed: 37354538
pii: 2806616
doi: 10.1001/jamahealthforum.2023.1744
pmc: PMC10290750
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e231744

Références

Am Econ J Appl Econ. 2019 Apr;11(2):302-332
pubmed: 31131073
J Health Econ. 2013 Dec;32(6):1289-300
pubmed: 24308880
Health Serv Res. 2012 Dec;47(6):2339-52
pubmed: 22578065
JAMA Health Forum. 2021 Dec 10;2(12):e214001
pubmed: 35977297
Health Aff (Millwood). 2012 Dec;31(12):2609-17
pubmed: 23213144
Am Econ Rev. 2018 Aug;108(8):2048-87
pubmed: 30091862
JAMA Health Forum. 2022 Sep 2;3(9):e222935
pubmed: 36218933
JAMA. 2022 Dec 6;328(21):2126-2135
pubmed: 36472594
Health Aff (Millwood). 2021 Jun;40(6):937-944
pubmed: 34097516

Auteurs

Aaron L Schwartz (AL)

Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Division of General Internal Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Center for Health Equity Research and Promotion, US Department of Veterans Affairs, Philadelphia, Pennsylvania.

Seyoun Kim (S)

The Wharton School, University of Pennsylvania, Philadelphia.

Amol S Navathe (AS)

Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Division of General Internal Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Center for Health Equity Research and Promotion, US Department of Veterans Affairs, Philadelphia, Pennsylvania.

Atul Gupta (A)

The Wharton School, University of Pennsylvania, Philadelphia.
National Bureau of Economic Research, Cambridge, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH